On 17–18 October 2025 in Berlin, the European Alliance for Personalised Medicine (EAPM) convened two key events aimed at accelerating the practical implementation of precision oncology across Europe:
- the Precision Medicine DIAlogue roundtable in partnership with DIA, and
- From Declarations to Delivery — Berlin Edition, EAPM’s high-level policy forum held alongside the ESMO Congress.
Together, these meetings brought regulators, payers, clinicians, diagnostic developers, industry, researchers, and patient advocates into a shared conversation focused on one central question: How do we ensure that diagnostic and therapeutic innovation reaches patients equitably and without delay?
Day 1 – Precision Medicine DIAlogue (17 October)
Venue: Hotel Bristol Berlin, Kurfürstendamm 27
This roundtable examined how to better align biomarker testing (Dx) with access to targeted therapies (Rx). Participants discussed persistent fragmentation between diagnostic readiness and treatment availability, particularly for fast-evolving biomarker-defined indications.
Key themes included:
- Regulatory and HTA coordination for companion diagnostics and next-generation assays
- Ensuring reimbursement frameworks support timely implementation
- Case examples demonstrating the integration of digital pathology and liquid biopsy into oncology pathways
- Data, evidence, and reporting standards that support wider adoption across health systems
The discussion reinforced the need for pragmatic and actionable solutions that can be adopted now—not at some distant future point.
Day 2 – From Declarations to Delivery: Berlin Edition (18 October)
Held during ESMO 2025, this policy forum focused on scaling liquid biopsy, minimal residual disease (MRD) assessment, and digital pathology so that innovations proven in trials translate into routine care.
Discussions centered on:
- Sustainable reimbursement models for advanced diagnostics
- Harmonised validation frameworks for digital and molecular testing
- Infrastructure and workforce readiness for decentralised and data-rich oncology care
- Embedding diagnostics early in clinical trial design to ensure pathways are ready at the time of drug approval
Speakers and participants underscored that equitable access must be the guiding metric of progress, not the number of pilots, studies, or technological breakthroughs.
Shared Takeaways
Across both meetings, several priorities clearly emerged:
- Diagnostics determine access. Timely and reliable biomarker testing is essential for precision oncology to function in practice.
- Implementation is a discipline. Procurement, training, validation, and data governance require structured planning—not ad-hoc adoption.
- Evidence must travel. Harmonised data and outcome standards are necessary for Europe-wide scaling.
- Equity is the measure of success. Patients should receive the same level of diagnostic and therapeutic opportunity regardless of where they live.
Next Steps
EAPM will:
- Develop a joint white paper with DIA summarising the policy and practice recommendations from the roundtable.
- Produce a summary brief from the Berlin side event to support dialogue with EU and national stakeholders.
- Continue convening multi-stakeholder forums to advance implementation pathways for precision oncology across Europe.
EAPM thanks all speakers, participants, and partners for their contributions.
Together, we are working to ensure that the innovations shaping the future of cancer care translate into tangible benefits for every patient, everywhere.